Article

An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine

2020-10-06

Abstract excerpt

<h4>BACKGROUND</h4> In-depth investigations of the safety and immunogenicity of inactivated SARS-CoV-2 vaccines are needed. <h4>METHOD</h4> In a phase I randomized, double-blinded, and placebo-controlled trial involving 192 healthy adults 18-59 years of age, two injections of three different doses (50 EU, 100 EU and 150 EU) of an inactivated SARS-CoV-2 vaccine or the placebo were administered intramuscularly with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9234a5f3-7629-5c83-b5f0-c38fcaf81578
DOI: 10.1101/2020.09.27.20189548

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccineDOI 10.1101/2020.09.27.20189548Read

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trialSemantic proximity Read

Phase 1 Study of Safety, Reactogenicity, and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate Administered as Inhalation Boost in SARS-CoV-2 Immunized AdultsSemantic proximity Read

Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III TrialSemantic proximity Read

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and diseaseSemantic proximity Read

Cellular immune response to SARS-CoV-2 infection in humans: a systematic reviewSemantic proximity Read

UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of ConcernSemantic proximity Read

Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescentsSemantic proximity Read

Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trialSemantic proximity Read

Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopesSemantic proximity Read

The Variation of SARS-CoV-2 and Advanced Research on Current VaccinesSemantic proximity Read

Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trialSemantic proximity Read

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trialSemantic proximity Read